If you have a family history of medullary thyroid cancer, multiple endocrine neoplasias, or acute pancreatitis, it is advisable to avoid using GLP-1 drugs
Closing: The Clinical Bottom Line on What Is BPC-157 BPC-157 is a synthetic signaling peptide with a narrow, high-confidence clinical use case: accelerating soft tissue repair, calming gut lining inflammation, and supporting joint recovery in patients who have stalled with standard care
The patients were diagnosed using the WHO criteria of post-COVID (long COVID) [52], namely: (a) individuals having a history of proven SARS-CoV-2 infection, (b) symptoms persisted beyond the acute phase of illness or manifested during recovery from acute COVID-19 infection, (c) symptoms lasted at least 2 months and are present 34 months after the onset of COVID-19, and (d) patients suffer from at least two symptoms that impair daily functioning including fatigue, memory or concentration problems, shortness of breath, chest pain, persistent cough, difficulty speaking, muscle aches, loss of smell or taste, affective symptoms, cognitive impairment, or fever [52]
References: National Center for Biotechnology Information (2023)